Statistik Asas
| CIK | 1092662 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Chembio Diagnostics Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-35569 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified i |
|
| May 4, 2023 |
CEMI / Chembio Diagnostics Inc. / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Chembio Diagnostics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 163572209 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340 (Name, Address |
|
| May 1, 2023 |
Exhibit 4 Joint Filing Agreement Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing of the Statement on Schedule 13D to which this Joint Filing Agreement is attached, and any amendments thereto that may be filed without the necessity of filing additional joint filing agreements. |
|
| May 1, 2023 |
CEMI / Chembio Diagnostics Inc. / Biosynex SA - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Chembio Diagnostics, Inc. (Name of Issuer) Common stock, $0.01 par value per share (Title of Class of Securities) 163572209 (CUSIP Number) Alexis Steinmetz c/o Biosynex SA 22 Boulevard Sébastien Brant 67400 Illkirch-Graffenstaden, France +33 (0)6 70 86 00 |
|
| April 27, 2023 |
As filed with the Securities and Exchange Commission on April 27, 2023 As filed with the Securities and Exchange Commission on April 27, 2023 Registration No. |
|
| April 27, 2023 |
AMENDED AND RESTATED OF THE SURVIVING CORPORATION EXHIBIT C AMENDED AND RESTATED BYLAWS OF THE SURVIVING CORPORATION BY-LAWS OF CHEMBIO DIAGNOSTICS, INC. |
|
| April 27, 2023 |
As filed with the Securities and Exchange Commission on April 27, 2023 As filed with the Securities and Exchange Commission on April 27, 2023 Registration No. |
|
| April 27, 2023 |
As filed with the Securities and Exchange Commission on April 27, 2023 As filed with the Securities and Exchange Commission on April 27, 2023 Registration No. |
|
| April 27, 2023 |
As filed with the Securities and Exchange Commission on April 27, 2023 As filed with the Securities and Exchange Commission on April 27, 2023 Registration No. |
|
| April 27, 2023 |
As filed with the Securities and Exchange Commission on April 27, 2023 As filed with the Securities and Exchange Commission on April 27, 2023 Registration No. |
|
| April 27, 2023 |
As filed with the Securities and Exchange Commission on April 27, 2023 As filed with the Securities and Exchange Commission on April 27, 2023 Registration No. |
|
| April 27, 2023 |
As filed with the Securities and Exchange Commission on April 27, 2023 As filed with the Securities and Exchange Commission on April 27, 2023 Registration No. |
|
| April 27, 2023 |
As filed with the Securities and Exchange Commission on April 27, 2023 As filed with the Securities and Exchange Commission on April 27, 2023 Registration No. |
|
| April 27, 2023 |
As filed with the Securities and Exchange Commission on April 27, 2023 As filed with the Securities and Exchange Commission on April 27, 2023 Registration No. |
|
| April 27, 2023 |
As filed with the Securities and Exchange Commission on April 27, 2023 As filed with the Securities and Exchange Commission on April 27, 2023 Registration No. |
|
| April 27, 2023 |
Exhibit 99.1 Biosynex Completes Acquisition of Chembio Diagnostics, Inc. Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America. STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) - Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced it has completed its acqu |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 9) CHEMBIO DIAGNOSTICS, INC. (Name of Subject Company (Issuer)) PROJECT MERCI MERGER SUB, INC. (Offeror) A wholly-owned indirect subsidiary of BIOSYNEX SA (Parent of Offeror) BIOSYNEX U.S. HOLDINGS, INC. |
|
| April 27, 2023 |
As filed with the Securities and Exchange Commission on April 27, 2023 As filed with the Securities and Exchange Commission on April 27, 2023 Registration No. |
|
| April 27, 2023 |
CHEMBIO DIAGNOSTICS, INC. April 27, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Chembio Diagnostics, Inc. Registration Statement on S-1 File No. 333-267320 Ladies and Gentlemen: This letter constitutes an application by Chembio Diagnostics, Inc., a public corporation organized under the laws of the State of Neva |
|
| April 27, 2023 |
Exhibit 3.1 |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 26, 2023 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-35569 88-0425691 (State or other jurisdiction of incorporation) (Commission |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9/A (Amendment No. 10) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 CHEMBIO DIAGNOSTICS, INC. (Name of Subject Company) CHEMBIO DIAGNOSTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 163572209 |
|
| April 24, 2023 |
CEMI / Chembio Diagnostics Inc. / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Chembio Diagnostics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 163572209 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340 (Name, Address |
|
| April 19, 2023 |
Chembio Stockholders Urged to Tender Shares Before 6:00 P.M., New York City Time, on April 26, 2023 Exhibit (a)(5)(K) Chembio Stockholders Urged to Tender Shares Before 6:00 P.M., New York City Time, on April 26, 2023 Failure to tender shares could result in the termination of the proposed merger between Chembio and Biosynex MEDFORD, N.Y., April 19, 2023 (GLOBE NEWSWIRE) - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 8) CHEMBIO DIAGNOSTICS, INC. (Name of Subject Company (Issuer)) PROJECT MERCI MERGER SUB, INC. (Offeror) A wholly-owned indirect subsidiary of BIOSYNEX SA (Parent of Offeror) BIOSYNEX U.S. HOLDINGS, INC. |
|
| April 19, 2023 |
On April 19, 2023, Chembio Diagnostics, Inc. (“ Exhibit (a)(5)(L) On April 19, 2023, Chembio Diagnostics, Inc. (“Chembio”) made the following announcement via Twitter regarding the cash tender offer (the “Offer”) by Project Merci Merger Sub, Inc. (“Purchaser”), a Nevada corporation and wholly-owned indirect subsidiary of Biosynex SA, a French société anonyme (“Parent”), to purchase all of the issued and outstanding shares of Chembio’s common st |
|
| April 19, 2023 |
Chembio Stockholders Urged to Tender Shares Before 6:00 P.M., New York City Time, on April 26, 2023 Exhibit (a)(5)(P) Chembio Stockholders Urged to Tender Shares Before 6:00 P.M., New York City Time, on April 26, 2023 Failure to tender shares could result in the termination of the proposed merger between Chembio and Biosynex MEDFORD, N.Y., April 19, 2023 (GLOBE NEWSWIRE) - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today |
|
| April 19, 2023 |
On April 19, 2023, Chembio Diagnostics, Inc. (“ Exhibit (a)(5)(Q) On April 19, 2023, Chembio Diagnostics, Inc. (“Chembio”) made the following announcement via Twitter regarding the cash tender offer (the “Offer”) by Project Merci Merger Sub, Inc. (“Purchaser”), a Nevada corporation and wholly-owned indirect subsidiary of Biosynex SA, a French société anonyme (“Parent”), to purchase all of the issued and outstanding shares of Chembio’s common st |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9/A (Amendment No. 9) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 CHEMBIO DIAGNOSTICS, INC. (Name of Subject Company) CHEMBIO DIAGNOSTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 163572209 |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9/A (Amendment No. 8) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 CHEMBIO DIAGNOSTICS, INC. (Name of Subject Company) CHEMBIO DIAGNOSTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 163572209 |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 7) CHEMBIO DIAGNOSTICS, INC. (Name of Subject Company (Issuer)) PROJECT MERCI MERGER SUB, INC. (Offeror) A wholly-owned indirect subsidiary of BIOSYNEX SA (Parent of Offeror) BIOSYNEX U.S. HOLDINGS, INC. |
|
| April 13, 2023 |
Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc. Exhibit (a)(5)(J) Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc. |
|
| April 10, 2023 |
Exhibit (a)(5)(M) Chembio Stockholders Reminded to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 2023 MEDFORD, N.Y., April 10, 2023 (GLOBE NEWSWIRE) - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. April 10 |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6) CHEMBIO DIAGNOSTICS, INC. (Name of Subject Company (Issuer)) PROJECT MERCI MERGER SUB, INC. (Offeror) A wholly-owned indirect subsidiary of BIOSYNEX SA (Parent of Offeror) BIOSYNEX U.S. HOLDINGS, INC. |
|
| April 10, 2023 |
Exhibit (a)(5)(H) Chembio Stockholders Reminded to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 2023 MEDFORD, N.Y., April 10, 2023 (GLOBE NEWSWIRE) - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. April 10 |
|
| April 10, 2023 |
On April 10, 2023, Chembio Diagnostics, Inc. (“ Exhibit (a)(5)(N) On April 10, 2023, Chembio Diagnostics, Inc. (“Chembio”) made the following announcement via Twitter regarding the cash tender offer (the “Offer”) by Project Merci Merger Sub, Inc. (“Purchaser”), a Nevada corporation and wholly-owned indirect subsidiary of Biosynex SA, a French société anonyme (“Parent”), to purchase all of the issued and outstanding shares of Chembio’s common st |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9/A (Amendment No. 7) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 CHEMBIO DIAGNOSTICS, INC. (Name of Subject Company) CHEMBIO DIAGNOSTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 163572209 |
|
| April 10, 2023 |
Exhibit (a)(5)(I) |
|
| April 7, 2023 |
CEMI / Chembio Diagnostics Inc. / PERCEPTIVE ADVISORS LLC - SC 13D Activist Investment SC 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment )* Chembio Diagnostics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 163572209 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340 (Name, Address and Telep |
|
| April 7, 2023 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Dated: April 7, 2023 PERCEP |
|
| April 6, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 6, 2023 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-35569 88-0425691 (State or other jurisdiction of incorporation) (Commission F |
|
| April 3, 2023 |
Chembio’s CEO Letter to Stockholders Exhibit(a)(5)(F) Chembio’s CEO Letter to Stockholders Reminder to Tender Shares Before 6:00 P. |
|
| April 3, 2023 |
On April 3, 2023, Chembio Diagnostics, Inc. (“ Exhibit (a)(5)(G) On April 3, 2023, Chembio Diagnostics, Inc. (“Chembio”) made the following announcement via Twitter regarding the cash tender offer (the “Offer”) by Project Merci Merger Sub, Inc. (“Purchaser”), a Nevada corporation and wholly-owned indirect subsidiary of Biosynex SA, a French société anonyme (“Parent”), to purchase all of the issued and outstanding shares of Chembio’s common sto |
|
| April 3, 2023 |
On April 3, 2023, Chembio Diagnostics, Inc. (“ Exhibit (a)(5)(L) On April 3, 2023, Chembio Diagnostics, Inc. (“Chembio”) made the following announcement via Twitter regarding the cash tender offer (the “Offer”) by Project Merci Merger Sub, Inc. (“Purchaser”), a Nevada corporation and wholly-owned indirect subsidiary of Biosynex SA, a French société anonyme (“Parent”), to purchase all of the issued and outstanding shares of Chembio’s common sto |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) CHEMBIO DIAGNOSTICS, INC. (Name of Subject Company (Issuer)) PROJECT MERCI MERGER SUB, INC. ((Offeror)) A wholly-owned indirect subsidiary of BIOSYNEX SA ((Parent of Offeror)) BIOSYNEX U.S. HOLDINGS, I |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9/A (Amendment No. 6) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 CHEMBIO DIAGNOSTICS, INC. (Name of Subject Company) CHEMBIO DIAGNOSTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 163572209 |
|
| April 3, 2023 |
Chembio’s CEO Letter to Stockholders Exhibit (a)(5)(K) Chembio’s CEO Letter to Stockholders Reminder to Tender Shares Before 6:00 P. |
|
| March 29, 2023 |
Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc. Exhibit (a)(5)(E) Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc. |
|
| March 29, 2023 |
UNITED STATES Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K UNITED STATES Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No.001-35569 CHEMBIO DIAGNOSTICS, INC. (Exact n |
|
| March 29, 2023 |
SC 14D9/A 1 brhc10050314sc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9/A (Amendment No. 5) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 CHEMBIO DIAGNOSTICS, INC. (Name of Subject Company) CHEMBIO DIAGNOSTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.01 per s |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) CHEMBIO DIAGNOSTICS, INC. (Name of Subject Company (Issuer)) PROJECT MERCI MERGER SUB, INC. (Offeror) A wholly-owned indirect subsidiary of BIOSYNEX SA (Parent of Offeror) BIOSYNEX U.S. HOLDINGS, INC. |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9/A (Amendment No. 4) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 CHEMBIO DIAGNOSTICS, INC. (Name of Subject Company) CHEMBIO DIAGNOSTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 163572209 |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) CHEMBIO DIAGNOSTICS, INC. (Name of Subject Company (Issuer)) PROJECT MERCI MERGER SUB, INC. (Name of Filing Persons (Offeror)) a wholly-owned indirect subsidiary of BIOSYNEX SA (Name of Filing Persons |
|
| March 21, 2023 |
Chembio Stockholders Reminded to Tender Shares Before 6:00 PM New York City Time, on March 28, 2023 Exhibit (a)(5)(d) Chembio Stockholders Reminded to Tender Shares Before 6:00 PM New York City Time, on March 28, 2023 MEDFORD, N. |
|
| March 21, 2023 |
Chembio Stockholders Reminded to Tender Shares Before 6:00 PM New York City Time, on March 28, 2023 Exhibit 99.1 Chembio Stockholders Reminded to Tender Shares Before 6:00 PM New York City Time, on March 28, 2023 MEDFORD, N.Y., March 21, 2023 (GLOBE NEWSWIRE) - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. March 21, 2023 F |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 CHEMBIO DIAGNOSTICS, INC. Nevada 001-35569 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identific |
|
| March 15, 2023 |
Chembio Announces Letter to Stockholders Regarding Tender Offer Exhibit (a)(5)(C) Chembio Announces Letter to Stockholders Regarding Tender Offer MEDFORD, NY, March 15, 2023 - Chembio Diagnostics, Inc. |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) CHEMBIO DIAGNOSTICS, INC. (Name of Subject Company (Issuer)) PROJECT MERCI MERGER SUB, INC. (Offeror) A wholly-owned indirect subsidiary of BIOSYNEX SA (Parent of Offeror) BIOSYNEX U.S. HOLDINGS, INC. |
|
| March 15, 2023 |
Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc. Exhibit (a)(5)(B) Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc. |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9/A (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 CHEMBIO DIAGNOSTICS, INC. (Name of Subject Company) CHEMBIO DIAGNOSTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 163572209 |
|
| March 15, 2023 |
Chembio Announces Letter to Stockholders Regarding Tender Offer Exhibit 99.1 Chembio Announces Letter to Stockholders Regarding Tender Offer MEDFORD, NY, March 15, 2023 - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. March 15, 2023 Fellow Chembio Stockholders, As previously disclosed, Ch |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 CHEMBIO DIAGNOSTICS, INC. Nevada 001-35569 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identific |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9/A (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 CHEMBIO DIAGNOSTICS, INC. (Name of Subject Company) CHEMBIO DIAGNOSTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 163572209 |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9/A (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 CHEMBIO DIAGNOSTICS, INC. (Name of Subject Company) CHEMBIO DIAGNOSTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 163572209 |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) CHEMBIO DIAGNOSTICS, INC. (Name of Subject Company (Issuer)) PROJECT MERCI MERGER SUB, INC. (Offeror) A wholly-owned indirect subsidiary of BIOSYNEX SA (Parent of Offeror) BIOSYNEX U.S. HOLDINGS, INC. |
|
| March 1, 2023 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table SCHEDULE TO (Rule 14d-100) CHEMBIO DIAGNOSTICS, INC. |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2023 CHEMBIO DIAGNOSTICS, INC. Nevada 001-35569 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identi |
|
| February 24, 2023 |
Chembio Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis System Exhibit 99.1 Chembio Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis System MEDFORD, NY, February 24, 2023 - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced receipt of a Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA) for the DPP HIV-Syphilis |
|
| February 14, 2023 |
NON-DISCLOSURE, INTELLECTUAL PROPERTY, NON-COMPETITION AND NON-SOLICITATION AGREEMENT Exhibit (e)(9) NON-DISCLOSURE, INTELLECTUAL PROPERTY, NON-COMPETITION AND NON-SOLICITATION AGREEMENT This Non-Disclosure, Intellectual Property, Non-Competition And Non-Solicitation Agreement (the “Agreement”) is entered into as of March 16, 2020 between Chembio Diagnostics, Inc. |
|
| February 14, 2023 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table SCHEDULE TO (Rule 14d-100) CHEMBIO DIAGNOSTICS, INC. |
|
| February 14, 2023 |
NON-DISCLOSURE, INTELLECTUAL PROPERTY, NON-COMPETITION AND NON-SOLICITATION AGREEMENT Exhibit (e)(14) NON-DISCLOSURE, INTELLECTUAL PROPERTY, NON-COMPETITION AND NON-SOLICITATION AGREEMENT This Non-Disclosure, Intellectual Property, Non-Competition and Non-Solicitation Agreement (the “Agreement”) is entered into on January 5, 2022 between Chembio Diagnostics, Inc. |
|
| February 14, 2023 |
NON-DISCLOSURE, INTELLECTUAL PROPERTY, NON-COMPETITION AND NON-SOLICITATION AGREEMENT Exhibit (e)(17) NON-DISCLOSURE, INTELLECTUAL PROPERTY, NON-COMPETITION AND NON-SOLICITATION AGREEMENT This Non-Disclosure, Intellectual Property, Non-Competition and Non-Solicitation Agreement (the “Agreement”) is entered into between Chembio Diagnostics, Inc. |
|
| February 14, 2023 |
CHEMBIO DIAGNOSTICS, INC. Executive Retention Agreement Exhibit (e)(16) CHEMBIO DIAGNOSTICS, INC. Executive Retention Agreement This Executive Retention Agreement (this “Agreement”) is entered into between Chembio Diagnostics, Inc., a Nevada corporation (the “Company”), and Charles Caso (the “Executive” and, together with the Company, the “Parties”) as of the date set forth on the signature page hereof(the “Effective Date”). Whereas, the Company consid |
|
| February 14, 2023 |
TABLE OF CONTENTS Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock of CHEMBIO DIAGNOSTICS, INC. |
|
| February 14, 2023 |
Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares. |
|
| February 14, 2023 |
Exhibit (a)(1)(C) LETTER TO BROKERS, DEALERS COMMERCIAL BANKS, TRUST COMPANIES AND OTHER NOMINEES Offer to Purchase for Cash All Outstanding Shares of Common Stock of CHEMBIO DIAGNOSTICS, INC. |
|
| February 14, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 CHEMBIO DIAGNOSTICS, INC. (Name of Subject Company) CHEMBIO DIAGNOSTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 163572209 (C |
|
| February 14, 2023 |
CHEMBIO DIAGNOSTICS, INC. Executive Retention Agreement Exhibit (e)(15) CHEMBIO DIAGNOSTICS, INC. Executive Retention Agreement This Executive Retention Agreement (this “Agreement”) is entered into between Chembio Diagnostics, Inc., a Nevada corporation (the “Company”), and Paul J. Angelico (the “Executive” and, together with the Company, the “Parties”) as of the date set forth on the signature page hereof (the “Effective Date”). Whereas, the Company c |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CHEMBIO DIAGNOSTICS, INC. (Name of Subject Company (Issuer)) PROJECT MERCI MERGER SUB, INC. (Offeror) A wholly-owned indirect subsidiary of BIOSYNEX SA (Parent of Offeror) BIOSYNEX U.S. HOLDINGS, INC. (Other Persons) (N |
|
| February 14, 2023 |
Letter of Transmittal to Tender Shares of Common Stock DIAGNOSTICS, INC. Exhibit (a)(1)(B) Letter of Transmittal to Tender Shares of Common Stock of CHEMBIO DIAGNOSTICS, INC. |
|
| February 14, 2023 |
Exhibit (a)(1)(D) LETTER TO CLIENTS Offer to Purchase for Cash All Outstanding Shares of Common Stock of CHEMBIO DIAGNOSTICS, INC. |
|
| February 14, 2023 |
CONFIDENTIALITY AND NON-DISCLOSURE AGREEMENT Exhibit (d)(2) CONFIDENTIALITY AND NON-DISCLOSURE AGREEMENT THIS CONFIDENTIALITY AND NON-DISCLOSURE AGREEMENT is entered into and effective as of May 25th, 2022, between “Cheetah” (“Company”), and Biosynex (“Alpha”). |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Chembio Diagnostics, Inc. (Name of Subject Company (Issuer)) Project Merci Merger Sub, Inc. (Name of Filing Person—Offeror) Biosynex SA Biosynex U.S. Holdings, Inc. (Names of Filing Persons—Other) Common Stock, par valu |
|
| January 31, 2023 |
Dear [Valued Customer / Partner], Exhibit 99.4 Dear [Valued Customer / Partner], Chembio announced the exciting news that it has entered into an agreement to be acquired by Biosynex SA (“Biosynex”) (EPA: ALBIO). A copy of the press release is attached. This is an important milestone in Chembio’s ongoing journey. The acquisition combines two leading rapid diagnostic test companies. Each company specializes in the development, manuf |
|
| January 31, 2023 |
For Internal Use Only; Not for Distribution Exhibit 99.1 For Internal Use Only; Not for Distribution Your Role and Guidelines As leaders of Chembio, you will play an important role in communicating with our customers, vendors, and partners about the benefits of this proposed combination and what it means for them, as well as what they can expect moving forward. We have included the following materials in this toolkit to ensure that you are |
|
| January 31, 2023 |
Exhibit 99.1 Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement Complementary Technologies, Product Portfolios, and Market Opportunities Expected to Represent Significant Growth Drivers Consolidated Manufacturing, Sales, Marketing, Operations to Provide Synergistic Cost Savings STRASBOURG, FRANCE and HAUPPAUGE, NY, January 31, 2023 – Biosynex SA (“Biosynex”) (EPA: ALBIO), a |
|
| January 31, 2023 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG BIOSYNEX SA, PROJECT MERCI MERGER SUB, INC. AND CHEMBIO DIAGNOSTICS, INC. DATED AS OF JANUARY 31, 2023 TABLE OF CONTENTS Pages Article I THE OFFER 2 Section 1.1 The Offer 2 Section 1.2 Company Actions 5 Article II THE MERGER 6 Section 2.1 The Merger 6 Section 2.2 Conversion of Shares of Capital Stock 7 Section 2.3 Surrender and Payment 8 Sectio |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 CHEMBIO DIAGNOSTICS, INC. (Name of Subject Company) CHEMBIO DIAGNOSTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 163572209 (CUSIP Number of Cla |
|
| January 31, 2023 |
Exhibit 99.2 Subject: Exciting Next Step for Chembio! Dear Chembio Colleagues, Today marks the beginning of an exciting next step for Chembio! As just announced publicly, we have entered into a definitive agreement to be acquired by Biosynex SA (“Biosynex”), under which Biosynex, through a subsidiary, will acquire Chembio for $0.45 per share, representing a premium of 27% compared to the closing p |
|
| January 31, 2023 |
Exhibit 99.1 Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement Complementary Technologies, Product Portfolios, and Market Opportunities Expected to Represent Significant Growth Drivers Consolidated Manufacturing, Sales, Marketing, Operations to Provide Synergistic Cost Savings STRASBOURG, FRANCE and HAUPPAUGE, NY, January 31, 2023 – Biosynex SA (“Biosynex”) (EPA: ALBIO), a |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2023 CHEMBIO DIAGNOSTICS, INC. Nevada 001-355669 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identi |
|
| January 31, 2023 |
Exhibit 99.3 Chembio Employee FAQ INTERNAL DISTRIBUTION ONLY. TO BE ATTACHED TO THE EMPLOYEE EMAIL AS A PDF AND DISTRIBUTED TO EMPLOYEES, AS NECESSARY 1. What was announced? • Chembio announced that we have entered into a definitive merger agreement under which Biosynex SA (“Biosynex”), a French market leader specializing in the design and distribution of rapid tests, through a subsidiary, will ac |
|
| November 4, 2022 |
CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Exhibit 99.1 Chembio Diagnostics Reports Third Quarter 2022 Financial Results HAUPPAUGE, NY, November 3, 2022 - Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended September 30, 2022. Recent Highlights • Achieved third quarter 2022 total revenue of $ |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 CHEMBIO DIAGNOSTICS, INC. Nevada 001-355669 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identi |
|
| November 4, 2022 |
Exhibit 99.2 Chembio Script November 3, 2022 Philip Taylor, Investor Relations Thank you, operator. Before we begin, let me remind you that the Company's remarks made during this conference call today, November 3, 2022, may include predictions, estimates or other information that might be considered forward-looking. These forward-looking statements represent Chembio’s current judgment for the futu |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to 001-355669 (Commission File Number) Chembio Diag |
|
| October 7, 2022 |
Exhibit 4.4 COMMON STOCK PURCHASE WARRANT CHEMBIO DIAGNOSTICS, INC. Warrant Shares: Issue Date: , 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Common Warrants Initial Exercise Date ( |
|
| October 7, 2022 |
Exhibit 107 Calculation of Filing Fee Tables ??Form S-1??.. (Form Type) ?????.????? Chembio Diagnostics Inc. ??????????.. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (1) |
|
| October 7, 2022 |
As filed with the Securities and Exchange Commission on October 7, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on October 7, 2022 Registration No. |
|
| October 7, 2022 |
Exhibit 1.1 SHARES OF COMMON STOCK, PRE-FUNDED WARRANTS (EXERCISABLE FOR WARRANT SHARES) AND COMMON WARRANTS (EXERCISABLE FOR WARRANT SHARES) OF CHEMBIO DIAGNOSTICS, INC. UNDERWRITING AGREEMENT , 2022 Craig-Hallum Capital Group LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto 222 South Ninth Street, Suite 350 Minneapolis, Minnesota 55402 Ladies and Gentleme |
|
| October 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2022 CHEMBIO DIAGNOSTICS, INC. Nevada 001-35569 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identifi |
|
| September 28, 2022 |
EX-1.1 2 ny20005230x3ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 SHARES OF COMMON STOCK, PRE-FUNDED WARRANTS (EXERCISABLE FOR WARRANT SHARES) AND COMMON WARRANTS (EXERCISABLE FOR WARRANT SHARES) OF CHEMBIO DIAGNOSTICS, INC. UNDERWRITING AGREEMENT , 2022 Craig-Hallum Capital Group LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto 222 South Ninth Street, Suite 350 Minne |
|
| September 28, 2022 |
Exhibit 4.4 COMMON STOCK PURCHASE WARRANT CHEMBIO DIAGNOSTICS, INC. Warrant Shares: Issue Date: , 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Common Warrants Initial Exercise Date ( |
|
| September 28, 2022 |
Exhibit 4.6 CHEMBIO DIAGNOSTICS, INC. and ACTION STOCK TRANSFER CORP. as Warrant Agent Warrant Agency Agreement Dated as of , 2022 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2022 (?Agreement?), between Chembio Diagnostics, Inc., a Nevada corporation (the ?Company?), and Action Stock Transfer Corp., a company, with offices at 2469 E. Fort Union Blvd., Suite 214, Salt Lake City |
|
| September 28, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Chembio Diagnostics Inc. |
|
| September 28, 2022 |
As filed with the Securities and Exchange Commission on September 28, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 28, 2022 Registration No. |
|
| September 28, 2022 |
Exhibit 4.5 PRE-FUNDED COMMON STOCK PURCHASE WARRANT CHEMBIO DIAGNOSTICS, INC. Warrant Shares: Issue Date: , 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the |
|
| September 7, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Chembio Diagnostics Inc. |
|
| September 7, 2022 |
As filed with the Securities and Exchange Commission on September 7, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 7, 2022 Registration No. |
|
| September 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2022 CHEMBIO DIAGNOSTICS, INC. Nevada 001-35569 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identi |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to 000-30379 (Commission File Number) Chembio Diagnostic |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 CHEMBIO DIAGNOSTICS, INC. Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identificat |
|
| August 4, 2022 |
CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Exhibit 99.1 Chembio Diagnostics Reports Second Quarter 2022 Financial Results HAUPPAUGE, NY, August 4, 2022 - Chembio Diagnostics, Inc. (?Chembio? or the ?Company?) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended June 30, 2022. Recent Highlights ? Achieved second quarter 2022 total revenue of $9.2 m |
|
| May 26, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 CHEMBIO DIAGNOSTICS, INC. Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identificatio |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to 000-30379 (Commission File Number) Chembio Diagnosti |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 CHEMBIO DIAGNOSTICS, INC. Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identification |
|
| May 5, 2022 |
CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Exhibit 99.1 Chembio Diagnostics Reports First Quarter 2022 Financial Results HAUPPAUGE, NY, May 5, 2022 - Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended March 31, 2022. Recent Highlights • Achieved total revenue of $18.8 million including recor |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2022 CHEMBIO DIAGNOSTICS, INC. Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identificati |
|
| March 3, 2022 |
CHEMBIO DIAGNOSTICS, INC. Subsidiaries of the Registrant Exhibit 21.1 CHEMBIO DIAGNOSTICS, INC. Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Incorporation Chembio Diagnostic Systems Inc. Delaware Chembio Diagnostics Brazil LLC Delaware Chembio Diagnostics Brazil Ltda. Brazil Chembio Diagnostics Malaysia Sdn. Bhd. Malaysia Chembio Diagnostics Germany Holdings GmbH Germany Chembio Diagnostics GmbH Germany |
|
| March 3, 2022 |
CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Exhibit 99.1 Chembio Diagnostics Reports Fourth Quarter and Full Year 2021 Financial Results HAUPPAUGE, NY, March 3, 2022 - Chembio Diagnostics, Inc. (?Chembio? or the ?Company?) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter and year ended December 31, 2021. Recent Highlights ? Achieved record quarterly |
|
| March 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 CHEMBIO DIAGNOSTICS, INC. Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identificati |
|
| March 3, 2022 |
UNITED STATES Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K UNITED STATES Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No.0-30379 CHEMBIO DIAGNOSTICS, INC. (Exact nam |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2022 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organizati |
|
| February 14, 2022 |
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT Exhibit 10.1 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This Amendment No. 1 to Employment Agreement dated February 9, 2022 (this ?Amendment?) is entered into between Chembio Diagnostics, Inc., a Nevada corporation (the ?Company?), and Richard L. Eberly (the ?Executive?) with respect to the Employment Agreement dated as of March 4, 2020 and effective as of March 16, 2020 (the ?Existing Agreement?) be |
|
| February 9, 2022 |
CEMI / Chembio Diagnostics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Chembio Diagnostics Inc. Title of Class of Securities: Common Stock CUSIP Number: 163572209 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| January 18, 2022 |
As filed with the Securities and Exchange Commission on January 14, 2022 As filed with the Securities and Exchange Commission on January 14, 2022 Registration No. |
|
| January 18, 2022 |
NOTICE OF GRANT OF NON-QUALIFIED STOCK OPTION AWARD CHEMBIO DIAGNOSTICS, INC. Exhibit 99.2 NOTICE OF GRANT OF NON-QUALIFIED STOCK OPTION AWARD CHEMBIO DIAGNOSTICS, INC. For Good and Valuable Consideration, Chembio Diagnostics, Inc. (the ?Company?) hereby grants to the Grantee designated in this Notice of Grant of Non-qualified Stock Option Award (this ?Notice?) an option (the ?Option?) to purchase the number of shares of the Common Stock of the Company set forth in this Not |
|
| January 18, 2022 |
NOTICE OF GRANT OF RESTRICTED STOCK UNIT AWARD CHEMBIO DIAGNOSTICS, INC. Exhibit 99.3 NOTICE OF GRANT OF RESTRICTED STOCK UNIT AWARD CHEMBIO DIAGNOSTICS, INC. For Good and Valuable Consideration, Chembio Diagnostics, Inc. (the ?Company?) hereby grants to the Grantee designated in this Notice of Grant of Restricted Stock Unit Award (this ?Notice?), a restricted stock unit award (the ?RSU?) with respect to the number of restricted stock units (the ?Units?) of the Company |
|
| January 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2021 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organizat |
|
| January 6, 2022 |
Chembio Diagnostics Announces Appointment of Larry Steenvoorden as Chief Financial Officer Exhibit 99.1 Chembio Diagnostics Announces Appointment of Larry Steenvoorden as Chief Financial Officer HAUPPAUGE, NY, January 5, 2022 - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the appointment of Larry Steenvoorden as Chief Financial Officer effective immediately. ?We are thrilled to welcome Larry to the |
|
| January 6, 2022 |
Chembio Diagnostics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Exhibit 99.2 Chembio Diagnostics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) HAUPPAUGE, NY, January 6, 2022 - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today reported that, in accordance with Nasdaq Listing Rule 5635(c)(4), it has granted a nonqualified stock option and a restricted stock unit award to Law |
|
| January 6, 2022 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into on December 30, 2021 and effective as of January 5, 2022 (the ?Effective Date?) between Chembio Diagnostics, Inc., a Nevada corporation (the ?Company?), and Lawrence J. Steenvoorden (the ?Executive? and, together with the Company, the ?Parties?). In consideration of the mutual covenants, promises and agr |
|
| December 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2021 (Exact name of registrant as specified in its charter) CHEMBIO DIAGNOSTICS, INC. Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organizat |
|
| December 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2021 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organizati |
|
| December 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2021 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organizat |
|
| December 6, 2021 |
Exhibit 10.1 AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT This Amendment No. 2 to Employment Agreement dated November 30, 2021 (this ?Amendment?) is entered into between Chembio Diagnostics, Inc., a Nevada corporation (the ?Company?), and Javan Esfandiari (?Employee?), with respect to the Employment Agreement dated as of March 5, 2016, as previously amended by Amendment No. 1 thereto dated as of March |
|
| November 22, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2021 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organizat |
|
| November 22, 2021 |
Chembio Diagnostic Systems Prevails in International Arbitration Against BioSure (UK) Ltd Exhibit 99.1 Chembio Diagnostic Systems Prevails in International Arbitration Against BioSure (UK) Ltd HAUPPAUGE, N.Y., Nov. 22, 2021 (GLOBE NEWSWIRE) ? Chembio Diagnostic Systems Inc. (?Chembio?), a subsidiary of Chembio Diagnostics, Inc. (Nasdaq: CEMI), received an international arbitration award Thursday, November 18, 2021 against BioSure (UK) Ltd, Chembio?s former UK distributor of HIV self-te |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 CHEMBIO DIAGNOSTICS, INC. Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identific |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to 000-30379 (Commission File Number) Chembio Diagn |
|
| November 4, 2021 |
CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS AS OF Exhibit 99.1 Chembio Diagnostics Reports Third Quarter 2021 Financial Results HAUPPAUGE, NY, November 4, 2021 - Chembio Diagnostics, Inc. (?Chembio? or the ?Company?) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended September 30, 2021. Recent Highlights ? Achieved third quarter 2021 total revenue of $ |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 CHEMBIO DIAGNOSTICS, INC. Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identific |
|
| October 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2021 CHEMBIO DIAGNOSTICS, INC. Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identific |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to 000-30379 (Commission File Number) Chembio Diagnostic |
|
| August 9, 2021 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-254261 AMENDMENT NO. 1 To Prospectus Supplement dated July 19, 2021 (to Prospectus dated May 5, 2021) ? $60,000,000 Common Stock This Amendment No. 1 to Prospectus Supplement, or this amendment, amends our prospectus supplement dated July 19, 2021, or the prospectus supplement. This amendment should be read in conjunction with the prospectus su |
|
| August 9, 2021 |
AMENDMENT NO. 1 AMENDED AND RESTATED BYLAWS CHEMBIO DIAGNOSTICS, INC. Exhibit 3.1 AMENDMENT NO. 1 TO AMENDED AND RESTATED BYLAWS OF CHEMBIO DIAGNOSTICS, INC. This First Amendment (this ?First Amendment?) to the Amended and Restated Bylaws (the ?Bylaws?) of Chembio Diagnostics, Inc., a Nevada corporation (the ?Corporation?), was approved by the Board of Directors of the Corporation (the ?Board?) on June 10, 2021. In accordance with Article IX of the Bylaws, this Firs |
|
| August 5, 2021 |
CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Exhibit 99.1 Chembio Diagnostics Reports Second Quarter 2021 Financial Results HAUPPAUGE, NY, August 5, 2021 - Chembio Diagnostics, Inc. (?Chembio? or the ?Company?) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended June 30, 2021. Recent Highlights ? Achieved second quarter 2021 total revenue of $6.5 m |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 CHEMBIO DIAGNOSTICS, INC Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identificati |
|
| July 22, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2021 CHEMBIO DIAGNOSTICS, INC. Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identificati |
|
| July 22, 2021 |
Chembio Diagnostics Receives $4 Million HIV Test Purchase Order Supported by The Global Fund Exhibit 99.1 Chembio Diagnostics Receives $4 Million HIV Test Purchase Order Supported by The Global Fund HAUPPAUGE, N.Y., July 22, 2021 (GLOBE NEWSWIRE) - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, announced its receipt today of a $4 million purchase order from the Partnership for Supply Chain Management (PFSCM), supported |
|
| July 21, 2021 |
Financial Statements and Exhibits, Other Events false001-35569001-35569555 WIRELESS BLVD.555 WIRELESS BLVD.HAUPPAUGEHAUPPAUGENYNY000109266200010926622021-07-202021-07-20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2021 CHEMBIO DIAGNOSTICS, INC. Nevada 0-30379 88-042 |
|
| July 21, 2021 |
EX-99.1 2 brhc10027112ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Chembio Diagnostics Receives $28.3 Million Purchase Order from Bio-Manguinhos for DPP SARS-CoV-2 Antigen Tests in Brazil HAUPPAUGE, N.Y., July 20, 2021 (GLOBE NEWSWIRE) - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, announced its receipt today of a $28.3 million purcha |
|
| July 19, 2021 |
AT THE MARKET OFFERING AGREEMENT July 19, 2021 EX-10.1 3 brhc10026983ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 AT THE MARKET OFFERING AGREEMENT July 19, 2021 Craig-Hallum Capital Group LLC 222 South 9th Street, Suite 350 Minneapolis, MN 55402 Ladies and Gentlemen: Chembio Diagnostics, Inc., a corporation organized under the laws of Nevada (the “Company”), confirms its agreement (this “Agreement”) with Craig-Hallum Capital Group LLC (the “Manager”) |
|
| July 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2021 CHEMBIO DIAGNOSTICS, INC. Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identificati |
|
| July 19, 2021 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-254261 PROSPECTUS SUPPLEMENT (to Prospectus dated May 5, 2021) ? $60,000,000 Common Stock We have entered into an At-The-Market Offering Agreement, or the ATM Agreement, with Craig-Hallum Capital Group LLC, or Craig-Hallum, relating to the sale of up to $60,000,000 of shares of our common stock, $0.01 par value per share, aggr |
|
| June 25, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2021 CHEMBIO DIAGNOSTICS, INC. Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identificati |
|
| June 10, 2021 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 CHEMBIO DIAGNOSTICS, INC. Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identificati |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to 000-30379 (Commission File Number) Chembio Diagnosti |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 CHEMBIO DIAGNOSTICS, INC. Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identification |
|
| May 6, 2021 |
Exhibit 99.1 Chembio Diagnostics Reports First Quarter 2021 Financial Results HAUPPAUGE, NY, May 6, 2021 - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended March 31, 2021. Chembio achieved first quarter 2021 total revenue of $8.7 million and product revenue of $4.0 million, r |
|
| May 3, 2021 |
May 3, 2021 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-35569 CHEMBIO DIAGN |
|
| March 15, 2021 |
S-3 1 nt10021637x1s3.htm S-3 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 15, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of i |
|
| March 12, 2021 |
As filed with the Securities and Exchange Commission on March 12, 2021 Registration No. |
|
| March 12, 2021 |
K&L Gates LLP State Street Financial Center One Lincoln Street Boston, Massachusetts 02111 K&L Gates LLP State Street Financial Center One Lincoln Street Boston, Massachusetts 02111 March 12, 2021 Via EDGAR Securities and Exchange Commission 100 F Street, NE Washington, DC 205549 Re: Chembio Diagnostics, Inc. |
|
| March 11, 2021 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 We have one class of securities registered under Section 12 of the Securities Exchange Act of 1934 (the ?Exchange Act?): common stock, $0.01 par value per share (?Common Stock?). Description of Common Stock The following is a description of the material terms and provisio |
|
| March 11, 2021 |
EX-22.1 4 brhc10021388ex22-1.htm EXHIBIT 22.1 Exhibit 22.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: 1. Registration Statement (Form S-3 No. 333-227398) of Chembio Diagnostics, Inc., 2. Registration Statement (Form S-3 No. 333- 215813) of Chembio Diagnostics, Inc., 3. Registration Statement (Form |
|
| March 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2021 CHEMBIO DIAGNOSTICS, INC. Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identificat |
|
| March 11, 2021 |
UNITED STATES Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No.0-30379 CHEMBIO DIAGNOSTICS, INC. (Exact nam |
|
| March 11, 2021 |
List of Subsidiaries of Chembio Diagnostics, Inc. Exhibit 21.1 CHEMBIO DIAGNOSTICS, INC. Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Incorporation Chembio Diagnostic Systems Inc. Delaware Chembio Diagnostics Brazil Holdings LLC Delaware Chembio Diagnostics Brazil Ltda. Brazil Chembio Diagnostics Malaysia Sdn. Bhd. Malaysia Chembio Diagnostics Germany Holdings GmbH Germany Chembio Diagnostics GmbH Germany |
|
| March 11, 2021 |
CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Exhibit 99.1 Chembio Diagnostics Reports Fourth Quarter and Full Year 2020 Financial Results HAUPPAUGE, NY, March 11, 2021 - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter and year ended December 31, 2020. Recent Accomplishments & Highlights • Achieved fourth quarter 2020 total r |
|
| March 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2021 CHEMBIO DIAGNOSTICS, INC. Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identificati |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Chembio Diagnostics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 163572209 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CHEMBIO DIAGNOSTICS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 163572209 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Chembio Diagnostics Inc. Title of Class of Securities: Common Stock CUSIP Number: 163572209 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) |
|
| December 17, 2020 |
Outside Director Compensation Policy of Chembio Diagnostics, adopted as of December 15, 2020 Exhibit 10.1 Chembio Diagnostics, Inc. Outside Director Compensation Policy The Board of Directors (the “Board”) of Chembio Diagnostics, Inc. (“Chembio”) has approved this Director Compensation Policy (this “Policy”) on, and effective as of, December 15, 2020. The objective of this Policy is to provide a total compensation package that enables Chembio to attract and retain, on a long-term basis, h |
|
| December 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2020 CHEMBIO DIAGNOSTICS, INC. Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identifi |
|
| December 4, 2020 |
Chembio Diagnostics Awarded $12.7 Million by BARDA for Development of Rapid DPP Respiratory Exhibit 99.1 Chembio Diagnostics Awarded $12.7 Million by BARDA for Development of Rapid DPP Respiratory Antigen Panel and 510(k) Submission of the Rapid DPP SARS-CoV-2 Antigen Test System HAUPPAUGE, NY, December 2, 2020 - Chembio Diagnostics, Inc. (Nasdaq: CEMI) a leading point-of-care diagnostic company focused on infectious diseases, today announced it has been awarded a contract from the Biome |
|
| December 4, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2020 CHEMBIO DIAGNOSTICS, INC. Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identific |
|
| November 5, 2020 |
Exhibit 99.1 - Chembio Diagnostics Reports Third Quarter 2020 Financial Results HAUPPAUGE, NY, November 5, 2020 - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended September 30, 2020. Recent Accomplishments & Highlights • Achieved total revenue of $10.3 million and product rev |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to 000-30379 (Commission File Number) Chembio Diagn |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organiza |
|
| August 7, 2020 |
Exhibit 10.2 Chembio Diagnostics Inc. 555 Wireless Blvd. Hauppauge, New York 11788 June 15, 2020 Ms. Gail S. Page [***] [***] Dear Gail: On behalf of Chembio Diagnostics Inc. (the “Company”), I am pleased to provide you with this letter agreement (this “Agreement”) setting forth the principal terms of the compensation package to be provided to you by the Company for your services as Executive Chai |
|
| August 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to 000-30379 (Commission File Number) Chembio Diagnostic |
|
| August 7, 2020 |
Exhibit 10.3 AMENDMENT TO LETTER AGREEMENT This Amendment to Letter Agreement dated June 30, 2020 (this “Amendment”) is entered into between Chembio Diagnostics, Inc., a Nevada corporation (the “Company”), and Gail S. Page (“Page”), with respect to their Letter Agreement dated as of June 15, 2020 (the “Agreement”). Capitalized terms used in the Amendment and defined in the Agreement shall have the |
|
| August 7, 2020 |
Exhibit 10.1 AMENDMENT TO LETTER AGREEMENT This Amendment to Letter Agreement dated June 16, 2020 (this “Amendment”) is entered into between Chembio Diagnostics, Inc., a Nevada corporation (the “Company”), and Gail S. Page (“Page”), with respect to their Letter Agreement dated as of January 17, 2020 (the “Agreement”). In consideration of the mutual agreements herein contained, the parties hereby c |
|
| August 6, 2020 |
CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Exhibit 99.1 Chembio Diagnostics Reports Second Quarter 2020 Financial Results HAUPPAUGE, NY, August 6, 2020 - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended June 30, 2020. Recent Accomplishments & Highlights • Announced plans to seek U.S. Food and Drug Administration (FDA) |
|
| August 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization |
|
| August 4, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2020 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) |
|
| July 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| July 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2020 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) |
|
| July 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| July 7, 2020 |
Chembio Diagnostics Announces Preliminary Estimates of Second Quarter 2020 Revenues Exhibit 99.1 Chembio Diagnostics Announces Preliminary Estimates of Second Quarter 2020 Revenues Company to Host Conference Call Tuesday, July 7 HAUPPAUGE, N.Y., July 6, 2020 - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading global point-of-care diagnostic company focused on infectious diseases, today announced its preliminary estimates of revenue results for the quarter ended June 30, 2020. T |
|
| July 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2020 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) |
|
| July 7, 2020 |
Exhibit 99.3 Chembio Announces Plans to Seek EUA Approval from FDA for Revised DPP COVID-19 IgM/IgG System and New DPP COVID-19 Antigen System HAUPPAUGE, N.Y., July 6, 2020 - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading global point-of-care diagnostic company focused on infectious diseases, today announced its plans to submit applications to the U.S. Food and Drug Administration (FDA) for E |
|
| July 7, 2020 |
Exhibit 99.4 Chembio Diagnostics Awarded BARDA Contract for Development of DPP COVID-19 Point-of-Care Antigen System HAUPPAUGE, NY, July 6, 2020 - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced it has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Offi |
|
| July 7, 2020 |
Exhibit 99.2 CHEMBIO SCRIPT – 7/7/2020 PHILIP TAYLOR, INVESTOR RELATIONS Thank you. Before we begin today, let me remind you that Chembio's remarks during this conference call today, July 7, 2020, will include forward-looking statements within the meaning of the Securities Act of 1933 concerning the current beliefs of the company. Forward-looking statements are subject to numerous assumptions, ris |
|
| June 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2020 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) |
|
| June 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| June 5, 2020 |
June 5, 2020 Mark L. Johnson [email protected] T +1 617 261 3260 F +1 617 261 3175 Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, DC 20549 Attention: Abby Adams and Celeste Murphy Re: Chembio Diagnostics, Inc. Preliminary Proxy Statement on Schedule 14A Filed May 29, 2020 File No. 001-355569 Ladies and Gentlemen: We are submitting this let |
|
| May 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 11, 2020 |
Exhibit 1.1 Execution Version 2,338,468 Shares CHEMBIO DIAGNOSTICS, INC. COMMON STOCK, PAR VALUE $0.01 PER SHARE UNDERWRITING AGREEMENT May 7, 2020 May 7, 2020 ROBERT W. BAIRD & CO. INCORPORATED As Representative of the Several Underwriters Identified in Schedule I Hereto c/o Robert W. Baird & Co. Incorporated 777 East Wisconsin Avenue Milwaukee, Wisconsin 53202 Ladies and Gentlemen: Chembio Diagn |
|
| May 11, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) ( |
|
| May 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 (April 20, 2020) CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdicti |
|
| May 8, 2020 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-227398 PROSPECTUS SUPPLEMENT (To Prospectus Dated October 3, 2018) 2,338,468 Shares CHEMBIO DIAGNOSTICS, INC. COMMON STOCK We are offering 2,338,468 shares of our common stock having an aggregate offering price of $27,476,999. Our common stock is listed on the Nasdaq Capital Market under the symbol “CEMI.” The last reported |
|
| May 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-35569 CHEMBIO DIAGN |
|
| May 6, 2020 |
TABLE OF CONTENTS The information in this preliminary prospectus is not complete and may be changed. |
|
| May 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to 000-30379 (Commission File Number) Chembio Diagnosti |
|
| May 4, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2020 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) ( |
|
| May 4, 2020 |
CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Exhibit 99.1 Chembio Diagnostics Reports First Quarter 2020 Financial Results HAUPPAUGE, NY, May 4, 2020 - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended March 31, 2020. Recent Accomplishments & Highlights • Attained FDA Emergency Use Authorization for the DPP COVID-19 IgM/ |
|
| May 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2020 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) ( |
|
| May 4, 2020 |
Chembio Diagnostics Attains CE Marking for DPP COVID-19 System for IgG and IgM Antibodies Exhibit 99.1 Chembio Diagnostics Attains CE Marking for DPP COVID-19 System for IgG and IgM Antibodies HAUPPAUGE, NY, May 4, 2020 - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced it has attained the CE Marking for its DPP COVID-19 System. The CE Marking represents the ability to commercialize the system within th |
|
| April 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-35569 CHEMBIO DIAGN |
|
| April 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2020 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization |
|
| April 2, 2020 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2020 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization |
|
| April 2, 2020 |
Exhibit 16.1 Tel: 631-501-9600 Fax: 631-501-1885 www.bdo.com 401 Broadhollow Road, Suite 201 Melville, NY 11747 April 1, 2020 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on March 30, 2020, to be filed by our former client, Chembio Diagnostics, Inc. We agree with t |
|
| March 20, 2020 |
Exhibit 99.2 Chembio Diagnostics Receives $4 Million Purchase Order from Bio-Manguinhos for Production of DPP COVID-19 IgM/IgG System in Brazil HAUPPAUGE, NY, March 20, 2020 - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced its receipt of a $4 million order from Bio-Manguinhos for the purchase of Chembio’s DPP COV |
|
| March 20, 2020 |
Chembio Diagnostics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Exhibit 99.1 Chembio Diagnostics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) HAUPPAUGE, NY, March 20, 2020 - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today reported that, in accordance with Nasdaq Listing Rule 5635(c)(4), it has granted a restricted stock unit award to Richard L. Eberly, Chembio’s new Chi |
|
| March 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2020 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization |
|
| March 20, 2020 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into on March 4, 2020 and effective as of March 16, 2020 (the “Effective Date”) between Chembio Diagnostics, Inc., a Nevada corporation (the “Company”), and Richard L. Eberly (the “Executive”). In consideration of the premises and mutual covenants in this Agreement and for other good and valuable consideratio |
|
| March 13, 2020 |
UNITED STATES Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 0-30379 CHEMBIO DIAGNOSTICS, INC. (Exact na |
|
| March 13, 2020 |
CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Exhibit 99.1 Chembio Diagnostics Reports Fourth Quarter and Full Year 2019 Financial Results HAUPPAUGE, N.Y., March 12, 2020 (GLOBE NEWSWIRE) - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter and year ended December 31, 2019. Recent Accomplishments & Highlights ● Achieved full yea |
|
| March 13, 2020 |
Exhibit 10.3 CHEMBIO DIAGNOSTICS, INC. 2019 OMNIBUS INCENTIVE PLAN Chembio Diagnostics, Inc., a Nevada corporation, sets forth herein the terms of its 2019 Omnibus Incentive Plan, as follows: 1. PURPOSE The Plan is intended to enhance the Company’s and its Affiliates’ (as defined herein) ability to attract and retain highly qualified officers, Non-Employee Directors (as defined herein), key employ |
|
| March 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2020 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization |
|
| March 13, 2020 |
List of Subsidiaries of Chembio Diagnostics, Inc. Exhibit 21.1 CHEMBIO DIAGNOSTICS, INC. Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Incorporation Chembio Diagnostic Systems Inc. Delaware Chembio Diagnostics Malaysia Sdn. Bhd. Malaysia opTricon GmbH Germany Brillant 3006, GmbH Germany Orangelife Comercio e Industria Ltda. Brazil |
|
| March 3, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2020 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of (Commission File Number) (I.R. |
|
| March 3, 2020 |
Chembio Diagnostics Provides Update on Regulatory Status of DPP HIV-Syphilis System Exhibit 99.1 Chembio Diagnostics Provides Update on Regulatory Status of DPP HIV-Syphilis System Medford, NY – March 3, 2020 - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, is providing an update on the FDA Premarket Approval (PMA) application for Chembio’s DPP HIV-Syphilis Assay System. The FDA has confirmed that, of the item |
|
| February 14, 2020 |
CEMI / Chembio Diagnostics, Inc / Nantahala Capital Management, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CHEMBIO DIAGNOSTICS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 163572209 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| January 21, 2020 |
Letter agreement dated January 17, 2020, between Chembio Diagnostics, Inc. and Gail S. Page Exhibit 10.1 Chembio Diagnostics, Inc. 555 Wireless Blvd. Hauppauge, New York 11788 January 17, 2020 Ms. Gail S. Page 4231 Westlake Drive Austin, Texas 78746 Dear Gail: On behalf of Chembio Diagnostics, Inc. (the “Company”), I am pleased to provide you with this letter agreement (this “Agreement”) setting forth the principal terms of the compensation package to be provided to you by the Company fo |
|
| January 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2020 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organizati |
|
| January 9, 2020 |
Exhibit 10.1 SEPARATION AND RELEASE AGREEMENT This Separation and Release Agreement (this “Agreement”), is being offered by Chembio Diagnostics, Inc., a Nevada corporation (the “Company”), to John J. Sperzel III (“Employee”) on January 6, 2020. This Agreement may be accepted by Employee by executing it without change and delivering it to the Company no later than 5 p.m., Eastern standard time, on |
|
| January 9, 2020 |
Chembio Diagnostics Announces CEO Transition Exhibit 99.1 Chembio Diagnostics Announces CEO Transition Medford, NY – January 9, 2020 - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced President and Chief Executive Officer John Sperzel has resigned for another opportunity. The Chembio Board of Directors has appointed Director Gail Page as Interim CEO and init |
|
| January 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2020 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organizatio |
|
| November 25, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2019 (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Numb |
|
| November 25, 2019 |
Chembio Diagnostics Completes Acquisition of Orangelife Exhibit 99.1 Chembio Diagnostics Completes Acquisition of Orangelife Medford, NY – November 25, 2019 - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that it has completed its previously announced acquisition of Orangelife Comercio e Industria Ltda., a Brazilian manufacturer and distributor of point-of-care diag |
|
| November 7, 2019 |
CEMI / Chembio Diagnostics, Inc 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to 000-30379 (Commission File Number) Chembio Diagn |
|
| November 7, 2019 |
Chembio Diagnostics Reports Third Quarter 2019 Financial Results Exhibit 99.1 Chembio Diagnostics Reports Third Quarter 2019 Financial Results MEDFORD, NY, November 7, 2019 - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended September 30, 2019. Recent Accomplishments & Highlights • Achieved total revenue of $9.7 million and product revenue |
|
| November 7, 2019 |
Chembio Diagnostics Enters into Definitive Agreement to Acquire Orangelife Exhibit 99.2 Chembio Diagnostics Enters into Definitive Agreement to Acquire Orangelife Acquisition will expand commercial presence and market opportunity in Brazil Medford, NY – November 7, 2019 - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that it has entered into a definitive agreement (the “Agreement”) to |
|
| November 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2019 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organizati |
|
| September 9, 2019 |
Exhibit 99.1 Corporate PresentationSeptember 2019 © 2018 Chembio. All Rights Reserved. | # © 2019 Chembio. All Rights Reserved. Page 1 Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of Chembio and its manage |
|
| September 9, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2019 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organizat |
|
| September 5, 2019 |
Exhibit 4.1 Execution Version NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN |
|
| September 5, 2019 |
Execution Version Exhibit 10.1 Credit Agreement and Guaranty Dated as of September 3, 2019 among Chembio Diagnostics, Inc., as the Borrower, The Guarantors from Time to Time Party hereto and Perceptive Credit Holdings II, LP and its successors and assigns party hereto, as Administrative Agent and as a Lender $20,000,000 Table of Contents Section Heading Page Article I Definitions 1 Section 1.01. C |
|
| September 5, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2019 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organizat |
|
| September 5, 2019 |
Chembio Diagnostics Announces $20 Million Term Loan with Perceptive Advisors Exhibit 99.1 Chembio Diagnostics Announces $20 Million Term Loan with Perceptive Advisors Medford, NY – September 4, 2019 - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the closing of a $20 million term loan with an affiliate of Perceptive Advisors, one of the world’s leading healthcare-focused investment firm |
|
| August 7, 2019 |
Exhibit 99.1 Corporate PresentationAugust 2019 © 2018 Chembio. All Rights Reserved. | # © 2019 Chembio. All Rights Reserved. Page * Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of Chembio and its managemen |
|
| August 7, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2019 CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Nevada 0-30379 88-0425691 (State or Other Jurisdiction of Incorporation or Organization |
